Helus Pharma (HELP) has priced an underwritten public offering of 10.3 million common shares at $4.85 apiece for aggregate gross proceeds of $50 million, the company said Wednesday.
The company said it will use the proceeds to advance its HLP003, HLP004 and HLP005 programs, including HLP003 for major depressive disorder, with phase 3 data expected in the fourth quarter.
The offering is expected to close Thursday.